Interim Results from the PRISM Randomized Phase 2 Dose Expansion Trial Evaluating 4D-150 in High Anti-VEGF Need Individuals with Neovascular (Wet) Age-Related Macular Degeneration
/wp-content/uploads/4dmt_logo.svg00Erik Allison/wp-content/uploads/4dmt_logo.svgErik Allison2024-05-07 11:13:542024-05-08 14:34:08Interim Results from the PRISM Randomized Phase 2 Dose Expansion Trial Evaluating 4D-150 in High Anti-VEGF Need Individuals with Neovascular (Wet) Age-Related Macular Degeneration